Stockscreener 앱 받기
153.08
0.51%
-0.79
시간 외 거래:
153.08
전일 마감가:
$153.87
열려 있는:
$156.07
하루 거래량:
1.46M
Relative Volume:
0.82
시가총액:
$290.96B
수익:
$54.66B
순이익/손실:
$13.58B
주가수익비율:
21.82
EPS:
7.0171
순현금흐름:
$16.05B
1주 성능:
+1.51%
1개월 성능:
+2.79%
6개월 성능:
+5.57%
1년 성능:
+31.03%
1일 변동 폭
$152.67
$156.41
1주일 범위
$149.33
$159.30
52주 변동 폭
$112.34
$170.46
노바티스 ADR Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
153.08 | 292.46B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,163.01 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.63 | 603.27B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
253.30 | 452.48B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.47 | 311.84B | 65.51B | 8.93B | 14.12B | 3.5532 |
노바티스 ADR Stock (NVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Argus | Hold → Buy |
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2026-01-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-12-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-09-12 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-08-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Underweight |
| 2025-02-04 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-12-04 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-09-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-09-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-09-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-19 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-23 | 개시 | BMO Capital Markets | Market Perform |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-09-25 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-03-27 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2023-01-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-12-05 | 업그레이드 | Stifel | Hold → Buy |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-05-09 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 재개 | Citigroup | Buy |
| 2021-12-14 | 다운그레이드 | Redburn | Buy → Neutral |
| 2021-12-06 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 개시 | Bernstein | Mkt Perform |
| 2021-03-10 | 다운그레이드 | Argus | Buy → Hold |
| 2021-02-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2020-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-03-10 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-04-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-04-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-10 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2018-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 재확인 | Leerink Partners | Outperform |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 개시 | Liberum | Buy |
모두보기
노바티스 ADR 주식(NVS)의 최신 뉴스
Novartis stock trades steady as Q2 2026 results highlight solid specialty medicines growth - Ad-hoc-news.de
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Novartis second quarter sales rise 3% to $14.4 billion - grafa.com
Earnings call transcript: Novartis tops Q2 2026 forecasts as shares rise - Investing.com
Novartis ADR earnings beat by $0.23, revenue topped estimates - Investing.com
NVS Stock Quote Price and Forecast - CNN
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Sahm
Novartis stock holds steady as pipeline and global reach underpin long-term growth - Ad-hoc-news.de
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis highlights drug pipeline strength as global healthcare demand grows - Ad-hoc-news.de
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Sahm
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - Barchart.com
Why Does Novartis AG-Sponsored ADR (NYSE:NVS) Track the NYSE Composite? - Kalkine Media
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout - ChartMill
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition - sharewise.com
Novartis to acquire Myricx Bio for $1.5 billion - grafa.com
10 Newly Overvalued Stocks this Week - Morningstar
What's Going on with Vera Therapeutics Stock on Monday? - Sahm
NVSNovartis AG ADR Options - Finviz
NOTA Forecast — Price Target — Prediction for 2027 - TradingView
Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States - Sahm
Novartis outlines growth path as pipeline and US exposure support long-term story - ad-hoc-news.de
Novartis stock holds steady after EAACI Rhapsido update. US trading stays in view. - Ad Hoc News
Novartis consensus picture on SIX, analysts keep a neutral view on the stock - Ad-hoc-news.de
Novartis opens the week with a cautious sector backdrop, shares in focus alongside Roche - AD HOC NEWS
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVS) - TradingView
Price to earnings forward of Novartis AG Sponsored ADR – MUN:NOTA - TradingView
Novartis oncology partnership with Antares, shares trade near analyst targets - Ad-hoc-news.de
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSC) - TradingView
Novartis focuses on oncology pipeline, shares track SMI pharma peers - ad-hoc-news.de
907122 Forecast — Price Target — Prediction for 2027 - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSD) - TradingView
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR Actuals & Estimates (BMFBOVESPA:N1VS34) - TradingView
NVS/N Forecast — Price Target — Prediction for 2027 - TradingView
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Sahm
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
Novartis highlights pipeline progress, shares trade steadily on NYSE - Ad-hoc-news.de
Novartis AG Stock (NVS) Closed Up by 3.04% on Jun 23: What Signal Does It Send? - TradingKey
Novartis refines India unit strategy, shares in focus on SIX trading - AD HOC NEWS
노바티스 ADR (NVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.96%
2.41%
자본화:
|
볼륨(24시간):